Free Trial
→ Is President Trump Lying To You With This? (From Colonial Metals) (Ad) Buy CNTA Stock  Free CNTA Stock Alerts

Centessa Pharmaceuticals (CNTA) Financials

Centessa Pharmaceuticals logo
$13.14 +0.07 (+0.54%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$13.48 +0.33 (+2.55%)
As of 05/30/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Centessa Pharmaceuticals

Annual Income Statements for Centessa Pharmaceuticals

This table shows Centessa Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2020 12/31/2019
Net Income / (Loss) Attributable to Common Shareholders		 -233 -148 -218 -11 -5.06
Consolidated Net Income / (Loss)		 -236 -151 -216 -11 -5.06
Net Income / (Loss) Continuing Operations		 -236 -151 -216 -11 -5.06
Total Pre-Tax Income 		-233 -176 -217 -11 -5.06
Total Operating Income		 -201 -171 -212 -10 -5.05
Total Gross Profit		 0.00 6.85 0.00 0.00 0.00
Total Revenue		 0.00 6.85 0.00 0.00 0.00
Operating Revenue		 0.00 6.85 0.00 - -
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 201 178 210 10 5.05
Selling, General & Admin Expense		 51 54 55 1.14 0.79
Research & Development Expense		 150 124 155 9.30 4.26
Total Other Income / (Expense), net		 -32 -4.86 -4.69 -0.22 -0.01
Interest Expense		 44 9.91 7.28 0.31 0.12
Interest & Investment Income		 14 10 0.24 -0.07 0.01
Other Income / (Expense), net		 -1.69 -5.43 2.34 0.16 0.11
Income Tax Expense		 2.84 -25 -0.75 0.00 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -5.44 -5.98 2.19 - -
Basic Earnings per Share		 ($2.06) ($1.57) ($2.31) $0.00 $0.00
Weighted Average Basic Shares Outstanding		 114.47M 96.18M 93.40M 0.00 0.00
Diluted Earnings per Share		 ($2.06) ($1.57) ($2.31) $0.00 $0.00
Weighted Average Diluted Shares Outstanding		 114.47M 96.18M 93.40M 0.00 0.00
Weighted Average Basic & Diluted Shares Outstanding		 133.18M 100.31M 94.96M - -

Quarterly Income Statements for Centessa Pharmaceuticals

This table shows Centessa Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -109 -42 -44 -38 -36 -39 -23 -50 -45 -54
Consolidated Net Income / (Loss)		 -111 -43 -44 -38 -37 -39 -25 -51 -43 -54
Net Income / (Loss) Continuing Operations		 -111 -43 -44 -38 -37 -39 -25 -51 -43 -54
Total Pre-Tax Income 		-110 -42 -43 -38 -36 -41 -49 -50 -44 -54
Total Operating Income		 -75 -46 -44 -36 -35 -40 -47 -49 -42 -49
Total Operating Expenses		 75 46 44 36 42 40 47 49 40 49
Selling, General & Admin Expense		 14 13 11 13 12 12 13 16 14 12
Research & Development Expense		 61 34 33 23 30 28 34 33 28 37
Total Other Income / (Expense), net		 -36 4.45 0.87 -1.48 -0.52 -1.27 -1.92 -1.16 -2.23 -4.99
Interest Expense		 37 2.56 2.53 2.53 2.57 2.54 2.45 2.35 2.20 1.92
Interest & Investment Income		 4.85 3.34 3.24 2.59 2.93 2.95 2.06 2.53 0.04 0.08
Other Income / (Expense), net		 -3.97 3.66 0.15 -1.54 -0.88 -1.68 -1.53 -1.35 -0.07 -3.14
Income Tax Expense		 1.05 0.61 0.71 0.48 1.14 -2.83 -24 0.68 -0.66 -0.14
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -4.24 -0.91 -0.03 -0.26 -3.74 0.33 -0.78 -1.80 - 1.11
Basic Earnings per Share		 ($0.91) ($0.37) ($0.40) ($0.38) ($0.38) ($0.40) ($0.26) ($0.53) ($0.45) ($0.57)
Weighted Average Basic Shares Outstanding		 114.47M 116.25M 109.49M 99.89M 96.18M 96.65M 95.16M 94.94M 93.40M 94.33M
Diluted Earnings per Share		 ($0.91) ($0.37) ($0.40) ($0.38) ($0.38) ($0.40) ($0.26) ($0.53) ($0.45) ($0.57)
Weighted Average Diluted Shares Outstanding		 114.47M 116.25M 109.49M 99.89M 96.18M 96.65M 95.16M 94.94M 93.40M 94.33M
Weighted Average Basic & Diluted Shares Outstanding		 133.18M 131.85M 113.31M 113.04M 100.31M 97.63M 97.40M 95.17M 94.96M 94.60M

Annual Cash Flow Statements for Centessa Pharmaceuticals

This table details how cash moves in and out of Centessa Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2020 12/31/2019
Net Change in Cash & Equivalents		 255 -266 -201 -9.34 3.70
Net Cash From Operating Activities		 -142 -160 -201 -11 -5.83
Net Cash From Continuing Operating Activities		 -142 -160 -201 -11 -5.83
Net Income / (Loss) Continuing Operations		 -236 -151 -216 -11 -5.06
Consolidated Net Income / (Loss)		 -236 -151 -216 -11 -5.06
Depreciation Expense		 0.94 0.81 0.13 0.00 0.01
Non-Cash Adjustments To Reconcile Net Income		 68 33 21 0.52 0.24
Changes in Operating Assets and Liabilities, net		 25 -43 -5.52 -0.49 -1.01
Net Cash From Investing Activities		 31 -127 -0.93 0.00 0.00
Net Cash From Continuing Investing Activities		 31 -127 -0.93 0.00 0.00
Purchase of Property, Plant & Equipment		 -0.03 -0.17 -1.14 0.00 0.00
Purchase of Investments		 -141 -265 0.00 - -
Sale and/or Maturity of Investments		 172 138 0.00 - -
Net Cash From Financing Activities		 365 21 0.46 1.36 9.01
Net Cash From Continuing Financing Activities		 365 21 0.46 1.36 9.01
Repayment of Debt		 -115 0.00 -0.26 0.00 0.00
Issuance of Debt		 109 0.00 - 1.36 3.84
Issuance of Common Equity		 360 21 0.00 0.00 0.00
Other Financing Activities, net		 11 0.31 0.72 0.00 0.00
Effect of Exchange Rate Changes		 1.23 0.62 -0.42 -0.08 0.52
Cash Interest Paid		 10 9.91 7.28 0.00 0.00
Cash Income Taxes Paid		 0.08 2.94 1.30 - -

Quarterly Cash Flow Statements for Centessa Pharmaceuticals

This table details how cash moves in and out of Centessa Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -12 268 9.15 -9.81 -43 26 -115 -134 -51 -39
Net Cash From Operating Activities		 -43 -21 -41 -37 -31 -37 -44 -48 -52 -39
Net Cash From Continuing Operating Activities		 -43 -21 -41 -37 -31 -37 -44 -48 -52 -39
Net Income / (Loss) Continuing Operations		 -111 -43 -44 -38 -37 -39 -25 -51 -43 -54
Consolidated Net Income / (Loss)		 -111 -43 -44 -38 -37 -39 -25 -51 -43 -54
Depreciation Expense		 0.23 0.24 0.24 0.24 0.25 0.24 0.24 0.09 0.04 0.04
Non-Cash Adjustments To Reconcile Net Income		 43 7.73 8.39 9.33 9.22 8.39 6.82 8.99 8.22 7.83
Changes in Operating Assets and Liabilities, net		 26 13 -5.39 -8.81 -3.67 -7.37 -26 -6.20 -17 6.93
Net Cash From Investing Activities		 25 45 -55 17 -18 49 -71 -86 -0.45 -0.02
Net Cash From Continuing Investing Activities		 25 45 -55 17 -18 49 -71 -86 -0.45 -0.02
Sale and/or Maturity of Investments		 25 45 65 37 52 86 - 0.00 - -
Net Cash From Financing Activities		 2.96 246 105 10 6.36 15 0.01 0.00 0.09 0.22
Net Cash From Continuing Financing Activities		 2.96 246 105 10 6.36 15 0.01 0.00 0.09 0.22
Repayment of Debt		 -112 -0.97 - - - - - - - -
Issuance of Common Equity		 -0.03 243 107 9.66 6.24 15 - 0.00 - -
Other Financing Activities, net		 5.34 4.25 0.80 0.84 0.12 0.18 0.01 0.00 0.09 0.22
Effect of Exchange Rate Changes		 3.03 -1.90 -0.12 0.22 -0.50 0.22 0.38 0.52 0.72 -0.44
Cash Interest Paid		 2.47 2.56 2.52 2.53 2.57 2.54 2.45 2.34 2.20 1.92
Cash Income Taxes Paid		 0.07 0.01 0.00 0.00 -0.00 0.24 2.57 0.14 0.44 -

Annual Balance Sheets for Centessa Pharmaceuticals

This table presents Centessa Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets		 577 360 444 630 12
Total Current Assets		 536 315 438 629 11
Cash & Equivalents		 383 128 394 595 7.23
Short-Term Investments		 99 129 - - -
Prepaid Expenses		 10 21 20 18 1.31
Other Current Assets		 44 - - - -
Plant, Property, & Equipment, net		 0.74 1.04 1.17 0.16 0.00
Total Noncurrent Assets		 40 44 1.88 0.70 0.55
Noncurrent Deferred & Refundable Income Taxes		 27 30 - - -
Other Noncurrent Operating Assets		 13 14 - - 0.55
Total Liabilities & Shareholders' Equity		 577 360 444 630 12
Total Liabilities		 175 124 108 138 8.62
Total Current Liabilities		 58 39 38 25 8.62
Accounts Payable		 7.14 12 14 8.07 1.03
Accrued Expenses		 51 28 25 17 1.05
Total Noncurrent Liabilities		 117 85 70 113 0.00
Long-Term Debt		 109 76 70 76 0.00
Other Noncurrent Operating Liabilities		 8.32 8.92 0.00 38 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 402 236 336 492 -22
Total Preferred & Common Equity		 402 236 336 492 0.00
Total Common Equity		 402 236 336 492 -22
Common Stock		 1,386 988 940 877 -22
Retained Earnings		 -989 -753 -602 -386 0.00
Accumulated Other Comprehensive Income / (Loss)		 4.21 1.49 -1.50 0.69 0.00

Quarterly Balance Sheets for Centessa Pharmaceuticals

This table presents Centessa Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 610 399 328 377 393 404 479
Total Current Assets		 568 356 284 332 350 384 477
Cash & Equivalents		 395 127 118 171 145 260 445
Short-Term Investments		 123 167 112 110 158 86 -
Prepaid Expenses		 16 19 18 23 20 18 12
Current Deferred & Refundable Income Taxes		 34 42 36 28 27 20 20
Plant, Property, & Equipment, net		 0.82 0.90 0.95 1.10 1.15 1.22 0.55
Total Noncurrent Assets		 41 42 43 44 41 18 1.81
Noncurrent Deferred & Refundable Income Taxes		 27 29 29 30 27 - -
Other Noncurrent Operating Assets		 13 14 14 14 15 18 -
Total Liabilities & Shareholders' Equity		 610 399 328 377 393 404 479
Total Liabilities		 111 112 113 118 116 111 106
Total Current Liabilities		 26 27 27 35 34 30 38
Accounts Payable		 7.44 5.32 7.50 11 11 14 11
Accrued Expenses		 19 21 20 24 23 15 27
Total Noncurrent Liabilities		 84 85 86 83 82 81 68
Long-Term Debt		 76 77 77 74 73 72 68
Other Noncurrent Operating Liabilities		 8.47 8.63 8.77 9.02 9.15 9.31 0.04
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 499 287 215 259 277 293 373
Total Preferred & Common Equity		 499 287 215 259 277 293 373
Total Common Equity		 499 287 215 259 277 293 373
Common Stock		 1,374 1,120 1,005 975 953 946 933
Retained Earnings		 -877 -835 -791 -716 -677 -653 -559
Accumulated Other Comprehensive Income / (Loss)		 2.10 1.60 1.62 0.78 0.95 -0.60 -1.70

Annual Metrics And Ratios for Centessa Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Centessa Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2020 12/31/2019
Growth Metrics		 - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -14.72% 16.15% 0.00% -108.11% 0.00%
EBIT Growth		 -14.73% 15.82% 0.00% -107.86% 0.00%
NOPAT Growth		 -17.38% 19.31% 0.00% -106.61% 0.00%
Net Income Growth		 -56.04% 30.12% 0.00% -110.69% 0.00%
EPS Growth		 -31.21% 32.03% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 11.41% 20.05% 0.00% -82.49% 0.00%
Free Cash Flow Firm Growth		 32.50% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 -48.90% 699.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -26.69% 3.21% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 -26.52% 3.08% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -24.37% 3.62% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -46.19% 4.02% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 -34.64% 4.27% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -9.02% 11.34% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 3.27% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -49.80% 6.43% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 100.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -2,566.77% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -2,499.39% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -2,578.59% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -2,204.65% 0.00% 0.00% 0.00%
Tax Burden Percent		 101.22% 85.78% 99.66% 100.00% 100.00%
Interest Burden Percent		 114.88% 99.68% 103.35% 103.68% 102.28%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -384.73% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -372.50% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 331.94% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -73.93% -52.79% -52.24% -344.19% 0.00%
Cash Return on Invested Capital (CROIC)		 -271.56% -540.24% 0.00% -1,175.70% 0.00%
Operating Return on Assets (OROA)		 0.00% -43.93% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -37.56% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -73.93% -52.79% -52.24% 2,491.21% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -58.71% -63.95% -64.32% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -141 -120 -149 -7.31 -3.54
NOPAT Margin		 0.00% -1,749.57% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -34.30% -12.23% -20.54% -419.38% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -27.57% -38.44% - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 784.05% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 1,815.34% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 2,599.39% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -203 -177 -210 -10 -4.95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -202 -176 -210 -10 -4.94
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 4.78 3.24 0.86 0.00 0.00
Price to Tangible Book Value (P/TBV)		 4.78 3.24 0.86 0.00 0.00
Price to Revenue (P/Rev)		 0.00 111.71 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 54.55 10.56 0.00 216.24 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 85.32 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.27 0.32 0.21 1.82 0.00
Long-Term Debt to Equity		 0.27 0.32 0.21 0.00 0.00
Financial Leverage		 -0.87 -0.89 -0.98 -0.52 0.00
Leverage Ratio		 1.47 1.41 1.30 3.78 0.00
Compound Leverage Factor		 1.69 1.40 1.34 3.92 0.00
Debt to Total Capital		 21.34% 24.27% 17.19% 64.49% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 64.49% 0.00%
Long-Term Debt to Total Capital		 21.34% 24.27% 17.19% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 292.50% 0.00%
Common Equity to Total Capital		 78.66% 75.73% 82.81% -257.00% 0.00%
Debt to EBITDA		 -0.54 -0.43 -0.33 -0.55 0.00
Net Debt to EBITDA		 1.85 1.03 1.54 0.16 0.00
Long-Term Debt to EBITDA		 -0.54 -0.43 -0.33 0.00 0.00
Debt to NOPAT		 -0.77 -0.63 -0.47 -0.77 0.00
Net Debt to NOPAT		 2.65 1.51 2.18 0.22 0.00
Long-Term Debt to NOPAT		 -0.77 -0.63 -0.47 0.00 0.00
Altman Z-Score		 4.00 0.10 -0.77 18.25 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 823.79% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 9.25 8.00 11.42 1.30 0.00
Quick Ratio		 8.31 6.51 10.27 0.84 0.00
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 -114 -168 0.00 -8.81 0.00
Operating Cash Flow to CapEx		 -417,808.82% -94,876.92% -17,638.17% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -2.57 -17.00 0.00 -28.41 0.00
Operating Cash Flow to Interest Expense		 -3.21 -16.19 -27.56 -34.29 -49.36
Operating Cash Flow Less CapEx to Interest Expense		 -3.22 -16.20 -27.72 -34.29 -49.36
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.02 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 6.21 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 28 55 6.93 1.50 0.00
Invested Capital Turnover		 0.00 0.22 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -27 48 0.00 1.50 0.00
Enterprise Value (EV)		 1,544 585 -34 324 0.00
Market Capitalization		 1,917 766 290 300 300
Book Value per Share		 $3.05 $2.42 $3.55 ($1.49) $0.00
Tangible Book Value per Share		 $3.05 $2.42 $3.55 ($1.49) $0.00
Total Capital		 510 312 406 8.73 0.00
Total Debt		 109 76 70 5.63 0.00
Total Long-Term Debt		 109 76 70 0.00 0.00
Net Debt		 -373 -181 -324 -1.60 0.00
Capital Expenditures (CapEx)		 0.03 0.17 1.14 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.77 19 5.77 0.95 0.00
Debt-free Net Working Capital (DFNWC)		 478 276 399 8.17 0.00
Net Working Capital (NWC)		 478 276 399 2.55 0.00
Net Nonoperating Expense (NNE)		 95 31 68 3.36 1.52
Net Nonoperating Obligations (NNO)		 -373 -181 -329 -1.60 0.00
Total Depreciation and Amortization (D&A)		 0.94 0.81 0.13 0.00 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 279.56% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 4,023.16% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 4,023.16% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 ($2.06) ($1.57) ($2.31) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 114.47M 96.18M 93.40M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($2.06) ($1.57) ($2.31) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 114.47M 96.18M 93.40M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 133.18M 100.31M 94.96M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -141 -120 -149 -7.31 -3.54
Normalized NOPAT Margin		 0.00% -1,749.57% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -2,570.28% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -4.59 -17.84 -28.85 -33.18 -41.93
NOPAT to Interest Expense		 -3.19 -12.10 -20.42 -23.57 -29.98
EBIT Less CapEx to Interest Expense		 -4.59 -17.86 -29.00 -33.18 -41.93
NOPAT Less CapEx to Interest Expense		 -3.19 -12.12 -20.57 -23.57 -29.98
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Centessa Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Centessa Pharmaceuticals' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -118.70% -2.06% 9.77% 25.43% 13.99% 20.12% 23.35% 5.40% 0.00% -29.63%
EBIT Growth		 -117.85% -2.04% 9.72% 25.08% 13.48% 19.71% 23.01% 5.28% 0.00% -29.71%
NOPAT Growth		 -112.01% -15.41% 6.46% 26.16% 15.44% 17.99% 31.27% 8.16% 0.00% -27.96%
Net Income Growth		 -202.22% -10.14% -76.07% 24.98% 14.68% 28.26% 61.51% 6.94% 0.00% -34.17%
EPS Growth		 -139.47% 7.50% -53.85% 28.30% 15.56% 29.82% 62.32% 11.67% 0.00% -26.67%
Operating Cash Flow Growth		 -37.84% 42.80% 7.90% 22.06% 39.78% 4.34% 26.41% 4.36% 0.00% 0.00%
Free Cash Flow Firm Growth		 65.63% 57.05% 30.68% -59.19% 0.00% -45.52% 2.59% 0.00% 0.00% -1,879.79%
Invested Capital Growth		 -48.90% 8.34% 48.17% 231.61% 699.00% 1,040.36% 1,661.18% 88.83% 0.00% 81.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -84.26% 2.49% -16.59% -4.40% 14.02% 13.79% 3.64% -20.41% 20.14% 17.27%
EBIT Q/Q Growth		 -83.78% 2.48% -16.47% -4.36% 13.92% 13.72% 3.34% -20.52% 20.12% 17.26%
NOPAT Q/Q Growth		 -60.72% -5.51% -21.86% -2.59% 12.51% 14.48% 3.80% -17.48% 15.14% 28.34%
Net Income Q/Q Growth		 -161.54% 2.85% -15.17% -3.28% 4.69% -55.30% 50.93% -17.47% 19.86% 16.68%
EPS Q/Q Growth		 -145.95% 7.50% -5.26% 0.00% 5.00% -53.85% 50.94% -17.78% 21.05% 17.39%
Operating Cash Flow Q/Q Growth		 -100.10% 47.29% -8.83% -20.08% 16.96% 15.14% 7.89% 7.23% -31.92% 34.72%
Free Cash Flow Firm Q/Q Growth		 31.78% 30.65% 22.39% 6.39% 14.75% -11.92% -78.23% 0.00% 100.00% 25.08%
Invested Capital Q/Q Growth		 -49.80% -17.84% 11.08% 11.54% 6.43% 12.37% 148.60% 168.74% 225.26% -310.46%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -522.54% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -513.32% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -526.13% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -537.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.95% 101.45% 101.64% 101.28% 103.21% 93.19% 50.85% 101.35% 98.49% 99.74%
Interest Burden Percent		 140.40% 98.17% 98.37% 99.84% 98.99% 99.02% 100.81% 99.63% 105.19% 103.54%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -79.02% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -74.23% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 66.15% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -73.93% 0.00% 0.00% 0.00% -12.87% -49.79% -49.57% -54.93% -52.24% 0.00%
Cash Return on Invested Capital (CROIC)		 -271.56% -216.71% -228.15% -383.25% -540.24% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -8.96% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -9.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -73.93% 0.00% 0.00% 0.00% -12.87% -49.79% -49.57% -54.93% -52.24% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -32.31% -54.83% -64.33% 0.00% -60.69% -62.42% -72.43% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -52 -32 -31 -25 -25 -28 -33 -34 -29 -34
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -359.33% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -21.34% -3.10% -5.81% -5.97% -4.79% -3.59% 2.48% -4.43% -4.27% -4.08%
Return On Investment Capital (ROIC_SIMPLE)		 -10.23% - - - -7.89% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 179.70% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 433.62% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 613.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -79 -43 -44 -38 -36 -42 -49 -50 -42 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -78 -43 -44 -37 -36 -42 -48 -50 -42 -52
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 4.78 3.72 3.45 5.25 3.24 2.41 2.13 1.25 0.86 1.02
Price to Tangible Book Value (P/TBV)		 4.78 3.72 3.45 5.25 3.24 2.41 2.13 1.25 0.86 1.02
Price to Revenue (P/Rev)		 0.00 271.25 144.27 164.71 111.71 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 54.55 25.11 11.22 15.79 10.56 8.03 7.75 4.88 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 206.65 112.41 142.33 85.32 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.27 0.15 0.27 0.36 0.32 0.29 0.27 0.24 0.21 0.18
Long-Term Debt to Equity		 0.27 0.15 0.27 0.36 0.32 0.29 0.27 0.24 0.21 0.18
Financial Leverage		 -0.87 -0.86 -0.80 -0.84 -0.89 -0.93 -0.93 -0.96 -0.98 -1.04
Leverage Ratio		 1.47 1.30 1.40 1.44 1.41 1.35 1.31 1.27 1.30 1.18
Compound Leverage Factor		 2.06 1.28 1.38 1.44 1.39 1.34 1.32 1.27 1.36 1.23
Debt to Total Capital		 21.34% 13.17% 21.05% 26.30% 24.27% 22.20% 20.95% 19.62% 17.19% 15.46%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 21.34% 13.17% 21.05% 26.30% 24.27% 22.20% 20.95% 19.62% 17.19% 15.46%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 78.66% 86.83% 78.95% 73.70% 75.73% 77.80% 79.05% 80.38% 82.81% 84.54%
Debt to EBITDA		 -0.54 -0.48 -0.48 -0.47 -0.43 -0.41 -0.38 -0.35 -0.33 0.00
Net Debt to EBITDA		 1.85 2.78 1.38 0.94 1.03 1.14 1.20 1.33 1.54 0.00
Long-Term Debt to EBITDA		 -0.54 -0.48 -0.48 -0.47 -0.43 -0.41 -0.38 -0.35 -0.33 0.00
Debt to NOPAT		 -0.77 -0.67 -0.70 -0.69 -0.63 -0.59 -0.56 -0.49 -0.47 0.00
Net Debt to NOPAT		 2.65 3.91 2.01 1.38 1.51 1.67 1.76 1.89 2.18 0.00
Long-Term Debt to NOPAT		 -0.77 -0.67 -0.70 -0.69 -0.63 -0.59 -0.56 -0.49 -0.47 0.00
Altman Z-Score		 4.71 8.92 3.02 3.20 1.39 1.10 1.18 0.36 0.48 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 9.25 21.52 13.29 10.37 8.00 9.51 10.35 12.95 11.42 12.49
Quick Ratio		 8.31 19.63 11.02 8.39 6.51 8.05 8.96 11.66 10.27 11.65
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -37 -53 -68 -73 -86 -77 -43 0.00 -59
Operating Cash Flow to CapEx		 0.00% -62,908.82% 0.00% 0.00% -110,892.86% -86,958.14% -440,620.00% -54,361.36% -7,908.59% -244,300.00%
Free Cash Flow to Firm to Interest Expense		 -0.69 -14.40 -21.03 -27.05 -28.44 -33.74 -31.27 -18.33 0.00 -30.65
Operating Cash Flow to Interest Expense		 -1.17 -8.36 -16.07 -14.74 -12.08 -14.72 -17.98 -20.40 -23.42 -20.34
Operating Cash Flow Less CapEx to Interest Expense		 -1.17 -8.38 -16.07 -14.74 -12.09 -14.73 -17.99 -20.44 -23.71 -20.35
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.02 0.02 0.02 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 7.13 6.69 6.31 6.21 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 28 56 69 62 55 52 46 19 6.93 -5.54
Invested Capital Turnover		 0.00 0.13 0.12 0.17 0.22 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -27 4.34 22 43 48 58 44 8.77 0.00 25
Enterprise Value (EV)		 1,544 1,416 770 975 585 418 359 91 -34 2.56
Market Capitalization		 1,917 1,859 989 1,129 766 625 589 366 290 379
Book Value per Share		 $3.05 $4.40 $2.54 $2.15 $2.42 $2.66 $2.91 $3.09 $3.55 $3.95
Tangible Book Value per Share		 $3.05 $4.40 $2.54 $2.15 $2.42 $2.66 $2.91 $3.09 $3.55 $3.95
Total Capital		 510 575 363 292 312 333 350 365 406 441
Total Debt		 109 76 77 77 76 74 73 72 70 68
Total Long-Term Debt		 109 76 77 77 76 74 73 72 70 68
Net Debt		 -373 -443 -218 -153 -181 -207 -230 -275 -324 -377
Capital Expenditures (CapEx)		 0.00 0.03 0.00 0.00 0.03 0.04 0.01 0.09 0.65 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.77 24 34 27 19 16 13 8.42 5.77 -6.04
Debt-free Net Working Capital (DFNWC)		 478 542 329 257 276 297 317 355 399 439
Net Working Capital (NWC)		 478 542 329 257 276 297 317 355 399 439
Net Nonoperating Expense (NNE)		 59 10 13 13 12 11 -8.03 17 14 20
Net Nonoperating Obligations (NNO)		 -373 -443 -218 -153 -181 -207 -230 -275 -329 -378
Total Depreciation and Amortization (D&A)		 0.23 0.24 0.24 0.24 0.25 0.24 0.24 0.09 0.04 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 343.05% 494.88% 392.00% 279.56% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 7,908.33% 4,797.13% 3,750.78% 4,023.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 7,908.33% 4,797.13% 3,750.78% 4,023.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.91) ($0.37) ($0.40) ($0.38) ($0.38) ($0.40) ($0.26) ($0.53) ($0.45) ($0.57)
Adjusted Weighted Average Basic Shares Outstanding		 114.47M 116.25M 109.49M 99.89M 96.18M 96.65M 95.16M 94.94M 93.40M 94.33M
Adjusted Diluted Earnings per Share		 ($0.91) ($0.37) ($0.40) ($0.38) ($0.38) ($0.40) ($0.26) ($0.53) ($0.45) ($0.57)
Adjusted Weighted Average Diluted Shares Outstanding		 114.47M 116.25M 109.49M 99.89M 96.18M 96.65M 95.16M 94.94M 93.40M 94.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 133.18M 131.85M 113.31M 113.04M 100.31M 97.63M 97.40M 95.17M 94.96M 94.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -52 -32 -31 -25 -25 -28 -33 -34 -29 -34
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -359.33% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -520.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -2.15 -16.72 -17.36 -14.88 -14.03 -16.48 -19.81 -21.42 -18.93 -27.14
NOPAT to Interest Expense		 -1.43 -12.70 -12.19 -9.99 -9.58 -11.08 -13.43 -14.59 -13.23 -17.86
EBIT Less CapEx to Interest Expense		 -2.15 -16.73 -17.36 -14.88 -14.04 -16.50 -19.82 -21.45 -19.22 -27.15
NOPAT Less CapEx to Interest Expense		 -1.43 -12.72 -12.19 -9.99 -9.59 -11.09 -13.44 -14.63 -13.52 -17.86
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Centessa Pharmaceuticals' Financials

When does Centessa Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Centessa Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Centessa Pharmaceuticals' net income changed over the last 4 years?

Centessa Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$235.76 million in 2024, rising from -$5.06 million in 2019. The previous period was -$151.09 million in 2023. See Centessa Pharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is Centessa Pharmaceuticals's operating income?
Centessa Pharmaceuticals's total operating income in 2024 was -$201.06 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $201.06 million
How has Centessa Pharmaceuticals revenue changed over the last 4 years?

Over the last 4 years, Centessa Pharmaceuticals' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Centessa Pharmaceuticals have?

Centessa Pharmaceuticals' total liabilities were at $175.25 million at the end of 2024, a 41.3% increase from 2023, and a 1,933.3% increase since 2020.

How much cash does Centessa Pharmaceuticals have?

In the past 4 years, Centessa Pharmaceuticals' cash and equivalents has ranged from $7.23 million in 2020 to $595.08 million in 2021, and is currently $383.22 million as of their latest financial filing in 2024.

How has Centessa Pharmaceuticals' book value per share changed over the last 4 years?

Over the last 4 years, Centessa Pharmaceuticals' book value per share changed from 0.00 in 2019 to 3.05 in 2024, a change of 304.6%.


Related Companies

This page (NASDAQ:CNTA) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored